Onconova Logo BLUE.jpg
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
28. Juni 2021 08:00 ET | Onconova Therapeutics, Inc.
Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation at Upcoming Virtual Events
09. September 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
23. Juli 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
23. Juni 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020
07. Mai 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
18. Februar 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
04. Februar 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
16. September 2019 07:30 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results
14. August 2019 07:30 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Presentations at Three Upcoming Conferences
28. Mai 2019 07:30 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 28, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...